Hier finden Sie wissenschaftliche Publikationen aus den Fraunhofer-Instituten.

Advances in automation for the production of clinical-grade mesenchymal stromal cells: The AUTOSTEM robotic platform

: Ochs, Jelena; Barry, Frank; Schmitt, Robert; Murphy, J. Mary

Fulltext urn:nbn:de:0011-n-4743825 (271 KByte PDF)
MD5 Fingerprint: 5d7cd1d8a0dbd08ffd0a78b0d10ffa45
(CC) by-nc-nd
Created on: 7.8.2018

Cell & Gene Therapy Insights 3 (2017), No.8, pp.739-748
ISSN: 2059-7800
European Commission EC
H2020-EU.3.1.3. - Treating and managing disease; 667932; AUTOSTEM
Journal Article, Electronic Publication
Fraunhofer IPT ()
automation; Roboter

Stem cell-based therapies are a central element of regenerative medicine and provide new treatment modalities for chronic and life-threatening conditions. Mesenchymal stem/stromal cells (MSCs) represent an important technology in regenerative medicine, although less developed with respect to clinical translation than hematopoietic stem cells (HSCs). MSC therapies may be based on the potential of the cells to differentiate to mesenchymal lineages or on their paracrine effects on host tissue. Both autologous and allogeneic applications are possible, the latter enabled by the low immunogenicity of the cells. Although stem cell therapy holds much promise for the treatment of chronic and debilitating diseases, there are still many obstacles to be overcome. In addition to the compelling need to generate strong and unambiguous clinical evidence, there are major technical gaps that must be filled. Chief among these is the development of manufacturing platforms for cell products that are efficient, cost effective and reproducible. Automated, robotic and closed production systems will provide the most efficient manufacturing strategy. Here we describe advances in automation for the clinical-scale production of MSCs and challenges associated with translating from lab-scale to automated large-scale manufacturing processes.